DATA
Q: How does Sanus benefit patients?
A: We help them to take control and organize their health data by building a personal EHR (First Opinion™). We help patients to act by comparing their personal health status to others in the database, this allows patients to arrive at proper differential diagnosis of their personal health issues and personalized therapy. Finally, we reimburse patients for sharing the essence of their medical experience with others.
Q: How do you protect personal data?
A: We do it in two layers: we remove all 18 HIPAA identifiers and, we reduce primary data to mathematics, suitable for bio-computation.
Q: Are there other companies already trying to monetize medical data?
A: There’s general recognition of the value of medical data but lack of knowledge how to do it. The main problem with all existing approaches is they attempt to own medical data, which is not consistent with recent regulations that emphasize the rights of the patients to own their data and the need to request consent to do anything with it. The “My Health, My Data” law went into effect on March 31st, 2024. To monetize medical data, we need to democratize it, which means empowering the patient to obtain not only their consent but also a new way to thinking about medical data as a personal asset.
Q: What does democratization of medicine mean?
A: Democratization of medicine means to focus on the patient who is now empowered to leverage their comprehensive medical data, to exercise personal freedom and to benefit financially. Empowerment of the patient has practical consequences enabling the patient to communicate more directly with providers, rather than being at the mercy of insurance.
Q: How can I collect all of my medical date and deliver it to you?
A: The latest regulations of Electronic Health Information export (EHI) requires medical providers to supply complete electronic medical records to the patient upon request. This output can easily become input for the First Opinion™ EHR.
Q: How does Sanus ensure correctness of medical data?
A: Our main source of data is medical providers who manage records using EHR software which can send records with security and API standardization to the patient. Obtaining “official” data is important to the verification process. Legacy data relies on scans of paper documents, but it is in the interest of the patient (financially and medically) to ensure correctness and completeness of data.
Q: What medical data can be utilized?
A: We can utilize any medical data, including doctor’s notes, blood analysis, medical imaging (x-rays, MRIs, CT scans), genomic data, etc. The exception is psychological information, which are protected even more stringently according to the latest regulations that came into effect at the end of March 2024. Electronic Health Information export | HealthIT.gov
FINANCE
Q: How does Sanus monetize medical data?
A: We collect revenue from sharing the mathematical essence of medical data and providing associated analytical tools, including those based on AI to analyze biomarkers, from genomics to imaging.
Q: Is Sanus purely a data company?
A: No. Our focus on the data allows us to accumulate value and to adapt to changing and emerging new technologies. We bring innovative 3rd party hardware and have plans for unique solutions that we will develop with the voice of the customer (patients). This hardware is part of our bio-computation capabilities that accumulate and analyze superior data. Finally, there is significant potential for financial instruments based on healthcare spending, which amounts to over $10T annually ($4.5T in the US alone).
Q: Who pays Sanus?
A: Hospitals and insurance pay to access our data to help provide personalized therapy for patients based on an ocean of relevant medical experience. Pharmaceutical companies pay for marketing drugs to patients, enrollment into clinical tries, and virtual drug screening.
Q: How do you reimburse patients?
A: Patients are reimbursed at the rate of 4% of the value of their medical data package annually. The dividends are paid in monthly installments. Patients receive the same dividend rate as investors who purchase equity in Sanus. This means the recurring revenue from data sharing effectively creates a personal financial instrument.
Q: How does Sanus ensure freedom to operate?
A: In the US, we maintain full compliance with HIPAA regulations, and in time will add SEC registration and others as we expand globally. We are not only first movers with a clear incentive plan that will enable us to build an unsurpassed product with more data and greater reimbursement for participants, but we have also filed a patent covering key provisions of BioFinTech and are in the process of building out our IP portfolio.
Q: What is the new financial instrument and how does it work?
A: Sanus will create digital collateral potentially using blockchain based on Solana or Ethereum. Our digital collateral will be convertible to equity, which yields dividends but requires KYC/AML compliance.